Thoraxklinik-Heidelberg gGmbH
11
1
3
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy
Role: collaborator
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Role: collaborator
Functional MRI for Monitoring Progression and Assessing Trends in ILD
Role: collaborator
Effects of the Kata® Inhalations-App on Inhaler Handling Errors, Adherence, and Asthma Control in Patients With Asthma.
Role: collaborator
NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing
Role: collaborator
Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease
Role: collaborator
Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC
Role: lead
Early Detection and Early Intervention Program in High-risk Patients to Avoid Invasive Long-term Ventilation
Role: collaborator
EBUS Guided Cryobiopsies With Ultrathin Cryoprobe in Patients With Peripheral Pulmonary Nodules - a Feasibility Study
Role: lead
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
Role: lead
22-gauge ProCore Needle v. Standard 22-gauge (P00030500)
Role: collaborator
All 11 trials loaded